OpiAID
About OpiAID
OpiAID develops a wearable device that collects biometric data to detect indicators of opioid overdose and withdrawal symptoms, integrating this information with electronic health records on a cloud-based platform. This technology provides clinicians with real-time insights to create personalized treatment plans, enhancing patient retention and optimizing billing opportunities for clinics.
```xml <problem> Opioid Use Disorder (OUD) treatment faces challenges in monitoring patients outside of clinical settings, leading to difficulties in detecting early signs of relapse or withdrawal. Traditional methods rely on patient self-reporting and infrequent clinic visits, which may not provide timely or accurate insights into a patient's condition. This lack of continuous monitoring can hinder the effectiveness of Medications for Opioid Use Disorder (MOUD) and contribute to higher dropout rates. </problem> <solution> OpiAID offers an AI-powered recovery intelligence platform that integrates data from commercially available wearable devices with clinic Electronic Health Records (EHR) to provide continuous, real-time monitoring of patients undergoing OUD treatment. The platform utilizes proprietary machine-learning algorithms to analyze biometric data collected from wrist-worn devices, quantifying withdrawal symptoms and detecting potential instances of acute substance use. Clinicians receive actionable alerts and insights through a user-friendly dashboard, enabling personalized treatment plans and timely interventions. By extending monitoring beyond the clinic walls, OpiAID aims to improve patient retention, enhance the safety and effectiveness of MOUD, and optimize billing opportunities for clinics through Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM). </solution> <features> - Integration with commercially available wrist-worn devices for continuous biometric data collection - Proprietary machine-learning algorithms for quantifying withdrawal symptoms and detecting potential substance use (pending FDA approval) - Real-time alerts and insights delivered through a user-friendly clinical dashboard - EHR integration for streamlined data management and clinical decision support - Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) capabilities for continuous patient oversight - Support for personalized treatment plans based on individual patient data and physiological responses - Mobile app (future development) to facilitate communication between patients, clinical care teams, and support networks </features> <target_audience> The primary target audience includes opioid treatment clinics, healthcare providers specializing in addiction medicine, and organizations seeking to improve patient retention and treatment outcomes in OUD programs. </target_audience> <revenue_model> OpiAID generates revenue by increasing patient retention for clinics, where each patient retained in treatment earns a clinic $8,400 annually, and through OPT Billing (RPM), which can generate $600,000 annually. </revenue_model> ```
What does OpiAID do?
OpiAID develops a wearable device that collects biometric data to detect indicators of opioid overdose and withdrawal symptoms, integrating this information with electronic health records on a cloud-based platform. This technology provides clinicians with real-time insights to create personalized treatment plans, enhancing patient retention and optimizing billing opportunities for clinics.
Where is OpiAID located?
OpiAID is based in Wilmington, United States.
When was OpiAID founded?
OpiAID was founded in 2018.
How much funding has OpiAID raised?
OpiAID has raised 2800000.
- Location
- Wilmington, United States
- Founded
- 2018
- Funding
- 2800000
- Employees
- 27 employees
- Major Investors
- National Institute on Drug Abuse (NIDA)